Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis

INTRODUCTION: Multiple agents are approved in the adjuvant setting of completely resected high-risk (stages IIC–IV) malignant melanoma. Subgroups may benefit differently depending on the agent used. We performed a systematic review and meta-analysis to evaluate the efficiency and tolerability of ava...

Descripción completa

Detalles Bibliográficos
Autores principales: Christofyllakis, Konstantinos, Pföhler, Claudia, Bewarder, Moritz, Müller, Cornelia S. L., Thurner, Lorenz, Rixecker, Torben, Vogt, Thomas, Stilgenbauer, Stephan, Yordanova, Krista, Kaddu-Mulindwa, Dominic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930562/
https://www.ncbi.nlm.nih.gov/pubmed/33680957
http://dx.doi.org/10.3389/fonc.2020.637161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930562/
https://www.ncbi.nlm.nih.gov/pubmed/33680957
http://dx.doi.org/10.3389/fonc.2020.637161

Ejemplares similares